Massachusetts-based medical device manufacturer Alere Inc. and its subsidiary Alere San Diego (Alere) have agreed to pay the United States $33.2 million to resolve allegations that Alere caused hospitals to submit false claims to Medicare and other federal healthcare programs relating to the use of materially unreliable point-of-care diagnostic testing devices.
The settlement agreement was announced today by Acting United States Attorney for the District of Maryland Stephen M. Schenning, Maureen Dixon, Special Agent in Charge for the Office of Inspector General for the Department of Health and Human Services, Robert Craig, Special Agent in Charge for the Defense Criminal Investigative Services, Mid-Atlantic Division and Mark McCormack, Special Agent in Charge for the Office of Criminal Investigations, Food and Drug Administration, Washington Field Division.